16+
Major trials tracked
Antibody-drug conjugates · Live ClinicalTrials.gov data
Trastuzumab deruxtecan (Enhertu) clinical trial pipeline
The timeline below tracks the 16 largest phase 2–4 trastuzumab deruxtecan (Enhertu) trials on ClinicalTrials.gov by enrolment, 8 of them actively recruiting. The next phase 3 primary completion among them is expected Jun 2028. Refreshed daily. Add up to four competitors to compare pipelines side by side.
8
Phase 3 trials
8
Actively recruiting
Jun 2028
Next phase 3 primary completion
7,009
Participants across trials
Daiichi Sankyo
Lead sponsor by trial count
trastuzumab deruxtecan (16)16 active2018–2035
trastuzumab deruxtecan
'18
'20
'22
'24
'26
'28
'30
'32
'34
trastuzumab deruxtecan
DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]P3
DG-03P2
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)P3
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast CancerP3
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland CancersP2
ARIADNEP2
ADAPTHER2-IVP2
A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing TumorsP2
DEMETHERP2
T-DXd Versus THP for Medium-risk HER2-positive Early Breast CancerP2
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerP3
SURVIVE HERoesP3
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)P3
THUMBP2
DESTINY-Lung06P3
MEGA-TACT-BC3P3
Upcoming readouts
11 ahead · trastuzumab deruxtecan
Select a trial to load its full ClinicalTrials.gov record.
Key trastuzumab deruxtecan trials
Top 12 of the 16 tracked phase 2–4 trials, ordered by phase and status. Trial names open the full ComplyRx trial page; NCT ids link to ClinicalTrials.gov.
Track trastuzumab deruxtecan with ComplyRx
Get an alert when a trial changes status, moves its completion date, or a new trial registers in scope. Checked nightly against ClinicalTrials.gov.
Related drug pipelines
FAQ
- How many clinical trials are running for trastuzumab deruxtecan?
- ClinicalTrials.gov lists more than 16 phase 2–4 trastuzumab deruxtecan trials. This page tracks the 16 largest by enrolment: 8 phase 2, 8 phase 3, and 0 phase 4 among them, with 8 actively recruiting. Updated daily.
- Are there clinical trials for Enhertu?
- Enhertu is the brand name for trastuzumab deruxtecan, so trastuzumab deruxtecan trials on ClinicalTrials.gov cover it. ClinicalTrials.gov lists more than 16 phase 2–4 trastuzumab deruxtecan trials. This page tracks the 16 largest by enrolment: 8 phase 2, 8 phase 3, and 0 phase 4 among them, with 8 actively recruiting. Updated daily.
- Where does this data come from?
- All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily.
- Can I compare trastuzumab deruxtecan against other drugs?
- Yes. The free ComplyRx Trial Pipeline tool compares up to five drugs side by side on one timeline, with PNG and PDF export. Add any competitor in the search box above.
Join the waitlist
Be the first to access ComplyRx
We'll let you know as soon as your spot opens to use ComplyRx.
By joining, you agree to our Privacy Policy.